Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy

Cell Reports Medicine - Tập 3 - Trang 100811 - 2022
Jonathan D. Herman1,2, Chuangqi Wang3, John Stephen Burke1, Yonatan Zur1, Hacheming Compere1, Jaewon Kang1, Ryan Macvicar1, Sabian Taylor1, Sally Shin1, Ian Frank4, Don Siegel5, Pablo Tebas6, Grace H. Choi7, Pamela A. Shaw8, Hyunah Yoon9, Liise-anne Pirofski9,10, Boris D. Julg1, Katharine J. Bar6, Douglas Lauffenburger3, Galit Alter
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
2Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USA
3Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
4Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
5Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
6Department of Medicine, University of Pennsylvania, Philadelphia, Pa. USA
7Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA
8Biostatistics Unit, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
9Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
10Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA

Tài liệu tham khảo

Dong, 2020, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis., 20, 533, 10.1016/S1473-3099(20)30120-1 Casadevall, 2020, The convalescent sera option for containing COVID-19, J. Clin. Invest., 130, 1545, 10.1172/JCI138003 Libster, 2021, Early high-titer plasma therapy to prevent severe covid-19 in older adults, N. Engl. J. Med., 384, 610, 10.1056/NEJMoa2033700 Joyner, 2021, Convalescent plasma antibody levels and the risk of death from covid-19, N. Engl. J. Med., 384, 1015, 10.1056/NEJMoa2031893 O'Donnell, 2021, A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J. Clin. Invest., 131, 150646, 10.1172/JCI150646 Yoon, 2021, Treatment of severe COVID-19 with convalescent plasma in bronx, NYC, JCI Insight, 6, e142270 Avendaño-Solá, 2021, A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia, J. Clin. Invest., 131, e152740, 10.1172/JCI152740 Salazar, 2021, Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG, Am. J. Pathol., 191, 90, 10.1016/j.ajpath.2020.10.008 Sullivan, 2021, Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma, medRxiv The RECOVERY Collaborative Group; Horby, P.W., Estcourt, L., Peto, L., Emberson, J.R., Staplin, N., Spata, E., Pessoa-Amorim, G., Campbell, M., Roddick, A., et al. Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. Preprint at medRxiv. https://doi.org/10.1101/2021.03.09.21252736. Abdelhady, 2021, Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19, JAMA, 326, 1690, 10.1001/jama.2021.18178 Bégin, 2021, Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial, Nat. Med., 27, 2012, 10.1038/s41591-021-01488-2 Herman, 2021, Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response, Nat. Commun., 12, 6853, 10.1038/s41467-021-27201-y Bar, 2021, A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia, J. Clin. Invest., 131, e155114, 10.1172/JCI155114 Focosi, 2021, Comparative analysis of antibody responses from COVID-19 convalescents receiving various vaccines reveals consistent high neutralizing activity for SARS-CoV-2 variant of concern omicron, medRxiv Schmidt, 2022, Plasma neutralization of the SARS-CoV-2 omicron variant, N. Engl. J. Med., 386, 599, 10.1056/NEJMc2119641 O'Connell, 2021 Wang, 2020, Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients, Clin. Infect. Dis., 71, ciaa721 Natarajan, 2021, Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma, mBio, 12, 007655, 10.1128/mBio.00765-21 Morgenlander, 2021, Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality, J. Clin. Invest., 131, 146927, 10.1172/JCI146927 Shaw, 2016, A rank test for bivariate time-to-event outcomes when one event is a surrogate, Stat. Med., 35, 3413, 10.1002/sim.6950 Chung, 2015, Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology, Cell, 163, 988, 10.1016/j.cell.2015.10.027 Zohar, 2020, Compromised humoral functional evolution tracks with SARS-CoV-2 mortality, Cell, 183, 1508, 10.1016/j.cell.2020.10.052 Zervou, 2021, SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection, J. Med. Virol., 93, 5409, 10.1002/jmv.27058 Bartsch, 2021, Humoral signatures of protective and pathological SARS-CoV-2 infection in children, Nat. Med., 27, 454, 10.1038/s41591-021-01263-3 Ma, 2020, Serum IgA, IgM, and IgG responses in COVID-19, Cell. Mol. Immunol., 17, 773, 10.1038/s41423-020-0474-z Yu, 2020, Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients, Eur. Respir. J., 56, 2001526, 10.1183/13993003.01526-2020 Frasca, 2017, Ageing and obesity similarly impair antibody responses, Clin. Exp. Immunol., 187, 64, 10.1111/cei.12824 Herman, 2021, Functional antibodies in COVID-19 convalescent plasma, medRxiv Weinreich, 2021, REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19, N. Engl. J. Med., 384, 238, 10.1056/NEJMoa2035002 Peluso, 2021, SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay, Sci. Adv., 7, eabh3409, 10.1126/sciadv.abh3409 Hansen, 2020, SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals, J. Immunol., 206, 109, 10.4049/jimmunol.2000898 Garcia-Beltran, 2021, COVID-19-neutralizing antibodies predict disease severity and survival, Cell, 184, 476, 10.1016/j.cell.2020.12.015 Koleba, 2006, Pharmacokinetics of intravenous immunoglobulin: a systematic review, Pharmacotherapy, 26, 813, 10.1592/phco.26.6.813 Arnold, 2007, The impact of glycosylation on the biological function and structure of human immunoglobulins, Annu. Rev. Immunol., 25, 21, 10.1146/annurev.immunol.25.022106.141702 Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr. Opin. Immunol., 20, 471, 10.1016/j.coi.2008.06.007 Jennewein, 2017, The immunoregulatory roles of antibody glycosylation, Trends Immunol., 38, 358, 10.1016/j.it.2017.02.004 Larsen, 2021, Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity, Science, 371, eabc8378, 10.1126/science.abc8378 Chakraborty, 2020, Proinflammatory IgG Fc structures in patients with severe COVID-19, Nat. Immunol., 22, 67, 10.1038/s41590-020-00828-7 Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 Anthony, 2008, Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc, Science, 320, 373, 10.1126/science.1154315 Karsten, 2012, Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1, Nat. Med., 18, 1401, 10.1038/nm.2862 Hoepel, 2021, High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages, Sci. Transl. Med., 13, eabf8654, 10.1126/scitranslmed.abf8654 Zhou, 2020, Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients, Natl. Sci. Rev., 7, 998, 10.1093/nsr/nwaa041 Grace, 2021, Antibody subclass and glycosylation shift following effective TB treatment, Front. Immunol., 12, 679973, 10.3389/fimmu.2021.679973 Ho, 2015, Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy, J. Infect. Dis., 211, 115, 10.1093/infdis/jiu388 Anthony, 2011, Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway, Nature, 475, 110, 10.1038/nature10134 Fiebiger, 2015, Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs, Proc. Natl. Acad. Sci. USA, 112, E2385, 10.1073/pnas.1505292112 Bournazos, 2020, Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection, Nature, 588, 485, 10.1038/s41586-020-2838-z Lofano, 2018, Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement, Sci. Immunol., 3, eaat7796, 10.1126/sciimmunol.aat7796 Gao, 2020, Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation, medRxiv Kang, 2021, A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation, Nat. Commun., 12, 2697, 10.1038/s41467-021-23036-9 Ma, 2021, Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection, Sci. Immunol., 6, eabh2259, 10.1126/sciimmunol.abh2259 Bernal, 2021, Molnupiravir for oral treatment of covid-19 in nonhospitalized patients, New Engl. J. Med. Agency, 2021 Raymond, 2011, Production of highly sialylated monoclonal antibodies Cameroni, 2021, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift, bioRxiv Aggarwal, 2021, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, medRxiv Planas, 2021, Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization, bioRxiv Cao, 2021, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, bioRxiv Ali, 2021, Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I/II randomized control trial, Eclinicalmedicine, 36, 100926, 10.1016/j.eclinm.2021.100926 Liu, 2021, Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants, Hum. Vaccines Immunother., 18, 1940652, 10.1080/21645515.2021.1940652 Kunze, 2021, Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors, Nat. Commun., 12, 4864, 10.1038/s41467-021-25113-5 Boesch, 2014, Highly parallel characterization of IgG Fc binding interactions, mAbs, 6, 915, 10.4161/mabs.28808 Brown, 2017, Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles, J. Immunol. Methods, 443, 33, 10.1016/j.jim.2017.01.010 Ackerman, 2011, A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples, J. Immunol. Methods, 366, 8, 10.1016/j.jim.2010.12.016 Ackerman, 2018, Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV, Nat. Med., 24, 1590, 10.1038/s41591-018-0161-0 Lu, 2016, A functional role for antibodies in tuberculosis, Cell, 167, 433, 10.1016/j.cell.2016.08.072 Fischinger, 2019, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation, J. Immunol. Methods, 1, 44 Karsten, 2019, A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis, J. Immunol. Methods, 471, 46, 10.1016/j.jim.2019.05.006 Alter, 2004, CD107a as a functional marker for the identification of natural killer cell activity, J. Immunol. Methods, 294, 15, 10.1016/j.jim.2004.08.008 Colucci, 2003, What does it take to make a natural killer?, Nat. Rev. Immunol., 3, 413, 10.1038/nri1088 Mahan, 2015, A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis, J. Immunol. Methods, 417, 34, 10.1016/j.jim.2014.12.004